IL5RA
Interleukin-5 receptor subunit alpha
As of the edition of 20 October 2026, IL5RA (interleukin-5 receptor subunit alpha, UniProt Q01344) has 1 drug tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q01344
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Immune system; Lungs and airways; Blood and lymph; Skin and connective tissue; Heart and blood vessels; Digestive system; Ear, nose and throat; Cancer
- Registered trials of its drugs
- 74
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Benralizumab | Marketed | Phase 4 | Ends 2031 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 2 |